紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床疗效观察
|
摘要
目的:观察晚期卵巢癌用紫杉醇联合顺铂腹腔和静脉双途径治疗效果。方法:抽取2017年7月～2018年8月某院收治的66例晚期卵巢癌患者作为研究对象,分析所有患者病例资料,通过不同的治疗措施将66例患者分为对照组与观察组各33例。对照组行紫杉醇治疗,观察组行紫杉醇联合顺铂腹腔和静脉双途径治疗,对比两组CA125控制有效率、不良反应发生率、临床疗效。结果:CA125控制有效率、临床疗效与对照组相比,观察组较高,P<0.05;不良反应发生率与对照组比较,观察组较低,P<0.05。结论:晚期卵巢癌用紫杉醇联合顺铂腹腔和静脉双途径治疗,不仅能提高CA125控制有效率与临床疗效,还可减少不良反应发生率,值得推广。
Objective: To observe the effect of paclitaxel combined with intraperitoneal cisplatin and venous approaches in the treatment of advanced ovarian cancer. Methods: 66 patients with advanced ovarian cancer admitted to a hospital from July 2008 to August 1818 were enrolled. The patient data were analyzed. 66 patients were divided into control group and observation group according to the different treatments. The control group(33 cases) received paclitaxel treatment, and the observation group(33 cases) underwent paclitaxel combined with intraperitoneal cisplatin and venous approaches. The efficacy of CA125 control, the incidence of adverse reactions, and clinical efficacy were compared. Results: CA125 control efficiency and clinical efficacy were higher in the observation group than in the control group, P<0.05. The incidence of adverse reactions was lower in the observation group than in the control group, P<0.05. Conclusion: The treatment of paclitaxel combined with intraperitoneal cisplatin and venous approaches in the advanced ovarian cancer can not only improve the efficiency and clinical efficacy of CA125 control, but also reduce the incidence of adverse reactions, which is worthy of promotion.
Objective: To observe the effect of paclitaxel combined with intraperitoneal cisplatin and venous approaches in the treatment of advanced ovarian cancer. Methods: 66 patients with advanced ovarian cancer admitted to a hospital from July 2008 to August 1818 were enrolled. The patient data were analyzed. 66 patients were divided into control group and observation group according to the different treatments. The control group(33 cases) received paclitaxel treatment, and the observation group(33 cases) underwent paclitaxel combined with intraperitoneal cisplatin and venous approaches. The efficacy of CA125 control, the incidence of adverse reactions, and clinical efficacy were compared. Results: CA125 control efficiency and clinical efficacy were higher in the observation group than in the control group, P<0.05. The incidence of adverse reactions was lower in the observation group than in the control group, P<0.05. Conclusion: The treatment of paclitaxel combined with intraperitoneal cisplatin and venous approaches in the advanced ovarian cancer can not only improve the efficiency and clinical efficacy of CA125 control, but also reduce the incidence of adverse reactions, which is worthy of promotion.
引文
1 赵红果,刘爱珍,宋芷霜,等.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的疗效分析.现代诊断与治疗,2018,29(5):710～712.
2 高嘉蔚,叶松.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床效果分析.中国现代药物应用,2017,11(2):88～90.
3 刘佳.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌效果分析.中华肿瘤防治杂志,2016,23(S1):192～193.
4 李慧,任素蓉,廖东彪,等.腹腔和静脉双途径应用紫杉醇加顺铂治疗晚期卵巢癌的临床观察.重庆医学,2007,12:1177～1178.
5 王鸿宇.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床观察.医学理论与实践,2016,29(10):1350～1351.
2 高嘉蔚,叶松.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床效果分析.中国现代药物应用,2017,11(2):88～90.
3 刘佳.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌效果分析.中华肿瘤防治杂志,2016,23(S1):192～193.
4 李慧,任素蓉,廖东彪,等.腹腔和静脉双途径应用紫杉醇加顺铂治疗晚期卵巢癌的临床观察.重庆医学,2007,12:1177～1178.
5 王鸿宇.紫杉醇联合顺铂腹腔和静脉双途径治疗晚期卵巢癌的临床观察.医学理论与实践,2016,29(10):1350～1351.